Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT03403725 Recruiting - Clinical trials for Metastatic Solid Tumors

MEN1309 Intravenous Infusion in Patients With CD205-positive Metastatic Solid Tumors and Relapsed or Refractory Non-Hodgkin Lymphoma Phase I Study

CD205-SHUTTLE
Start date: August 28, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this clinical trial is to identify the highest dose of MEN1309 drug with acceptable safety profile and that can be used in patients affected by CD205-positive solid tumors and Non-Hodgkin Lymphoma

NCT ID: NCT03401853 Not yet recruiting - Clinical trials for Refractory Diffuse Large B-Cell Lymphoma

Rituximab and Pembrolizumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma

Start date: March 15, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well rituximab and pembrolizumab work in treating patients with follicular lymphoma or diffuse large B cell lymphoma that has come back or does not respond to treatment. Monoclonal antibodies, such as pembrolizumab and rituximab, may interfere with the ability of cancer cells to grow and spread.

NCT ID: NCT03399747 Enrolling by invitation - Clinical trials for Diffuse Large B-cell Lymphoma

Abbreviated 3 Cycles of Rituximab Plus CHOP(Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy in Patients With Completely Excised LocalizedGastrointestinal CD(Cluster of Differentiation Antigen)20(+) Diffuse Large B-cell Lymphoma

Start date: December 7, 2016
Phase: Phase 2
Study type: Interventional

Phase 2 Study of Abbreviated 3 Cycles of Rituximab plus CHOP (Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy in Patients with Completely Excised Localized Gastrointestinal CD20 (+) Diffuse Large B-cell Lymphoma(SATURDAY STUDY)

NCT ID: NCT03399513 Not yet recruiting - Clinical trials for Diffuse Large B Cell Lymphoma

Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma

R-CHOEP-brut
Start date: February 2018
Phase: Phase 2
Study type: Interventional

This study will investigate if treatment results obtained with R-CHOEP in young high-risk patients with diffuse large B-cell lymphoma can be further improved by the addition of ibrutinib to this regimen.

NCT ID: NCT03398967 Recruiting - B Cell Lymphoma Clinical Trials

A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma

Start date: January 2, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

CD19-directed CAR-T cell therapy has shown promising results for the treatment of relapsed or refractory B-cell malignancies; however, a subset of patients relapse due to the loss of CD19 in tumor cells. Dual Specificity CD19 and CD20 or CD22 CAR-T cells can recognize and kill the CD19 negative malignant cells through recognition of CD20 or CD22. This is a phase 1/2 study designed to determine the safety of the allogenic gene-edited dual specificity CD19 and CD20 or CD22 CAR-T cells and the feasibility of making enough to treat patients with relapsed or refractory hematological malignancies.

NCT ID: NCT03397953 Recruiting - Clinical trials for Anaplastic Large Cell Lymphoma

Vinorelbine for ACLC

Start date: November 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the effectivity and safety of vinorelbine in the treatment of relapsed / advanced ALCL in children and adolescents.

NCT ID: NCT03391726 Recruiting - Clinical trials for Relapsed or Refractory B-cell Lymphoma

CART-19 Cells for R/R B-cell Lymphoma

CCFRRBL
Start date: January 1, 2016
Phase: Phase 2/Phase 3
Study type: Interventional

Relapsed/Refractory B Cell Lymphoma is a challenge to be treated, however,CART-19 cells could be very promosing. This study aims to assess the safety and toxicity of CART-19 cells for patients with relapse or refractory B cell lymphoma.

NCT ID: NCT03391466 Recruiting - Clinical trials for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

A Study Evaluating the Efficacy of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma

ZUMA-7
Start date: December 14, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate whether axicabtagene ciloleucel therapy improves the clinical outcome compared with standard of care second-line therapy in patients with relapsed/refractory DLBCL.

NCT ID: NCT03385226 Not yet recruiting - Clinical trials for Cutaneous T Cell Lymphoma

A Trial Assessing the Effect of Pembrolizumab Combined With Radiotherapy in Patients With Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS)

PORT
Start date: April 2018
Phase: Phase 2
Study type: Interventional

Trial Subjects (patients), will receive single infusions of pembrolizumab every 3 weeks until disease progression or unacceptable toxicity develops. They will receive radiotherapy at week 12.

NCT ID: NCT03384654 Not yet recruiting - Clinical trials for Precursor Cell Lymphoblastic Leukemia-Lymphoma

A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Start date: April 1, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy of daratumumab in addition to standard chemotherapy in relapsed/refractory B-cell acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LL) and T-cell ALL/LL as measured by the complete response (CR) rate.